XROMI
Growthhydroxyurea
NDAORALSOLUTIONPriority Review
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Pharmacologic Class:
Antimetabolite
Clinical Trials (5)
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Started Jul 2024
300 enrolled
Essential Thrombocythemia
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Started Dec 2023
340 enrolled
Essential Thrombocythemia
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
Started Nov 2023
400 enrolled
Sickle Cell Anemia in ChildrenSickle Cell Disease
Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.
Started Nov 2020
1,576 enrolled
Polycythemia Vera (PV)
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
Started Aug 2020
174 enrolled
Essential Thrombocythemia
Loss of Exclusivity
LOE Date
Dec 23, 2041
192 months away
Patent Expiry
Dec 23, 2041
Exclusivity Expiry
Apr 4, 2031
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 12409156 | Dec 23, 2041 | Product | — |